Scarica l'app Stockscreener
294.60
2.00%
5.775
Dopo l'orario di chiusura:
294.60
0.005
+0.00%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Ligand Pharmaceuticals Inc Borsa (LGND) Ultime notizie
Bank of America Corp DE Raises Holdings in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Pharmaceuticals(LGND.US) Officer Sells US$9.24 Million in Common Stock - moomoo.com
Ligand Pharmaceuticals (NASDAQ:LGND) Director Jason Haas Sells 7,138 Shares - MarketBeat
Insider Selling: Ligand Pharmaceuticals (NASDAQ:LGND) CFO Sells 31,641 Shares of Stock - MarketBeat
Ligand Pharmaceuticals CFO Octavio Espinoza sells $9.2m in shares - Investing.com
Ligand Pharmaceuticals CFO Octavio Espinoza sells $9.2m in shares By Investing.com - Investing.com UK
Ligand Pharmaceuticals (LGND) director exercises options and sells 7,138 shares - Stock Titan
LGND Initiated Coverage by Leerink Partners -- Rating Outperform - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
Ligand Pharmaceuticals (NASDAQ:LGND) Now Covered by Leerink Partners - MarketBeat
Stifel reiterates Buy on Ligand Pharma stock, $332 target By Investing.com - Investing.com Canada
Ligand Pharmaceuticals (LGND) Stock Trades Below Fair Value Following A 337% Run - Yahoo Finance
Ligand Pharmaceuticals (LGND) Reaffirms 2026 Guidance, Is The Stock Fully Priced? - Yahoo Finance
Invesco Ltd. (LGND holder) reports 6.1% beneficial stake in Ligand Pharmaceuticals - Stock Titan
Ligand (LGND) Q2 2026 Earnings Call Transcript - The Globe and Mail
Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts - Yahoo Finance
Enterprise value to EBIT forward of Ligand Pharmaceuticals Incorporated – OTC:LGNZZ - TradingView
LIGAND PHARMACEUTICALS INC SEC Filing (Aug 12, 2026) - Stock Titan
Ligand (NASDAQ: LGND) holder Jason Haas files Form 144 for stock sale - Stock Titan
Citi Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $390 - moomoo.com
Q1 2026 Ligand Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Q4 2025 Ligand Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Ligand Pharmaceuticals Incorporated (LGND) stock price, news, quote and history - Yahoo Finance UK
Ligand Pharmaceuticals Incorporated (LGND) Stock Price, News, Quote & History - Yahoo! Finance Canada
Ligand Pharmaceuticals (LGND) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
LGND: XOMA Acquisition Closed - Smartkarma
Weekly Recap: Q2 revenue, royalty growth and $700M convertible notes - TradingView
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Issues Quarterly Earnings Results - MarketBeat
A Quick Look at Today's Ratings for Ligand Pharmaceuticals(LGND.US), With a Forecast Between $326 to $370 - moomoo.com
California State Teachers Retirement System Acquires 4,987 Shares of Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
LGND SWOT Analysis: Strong Revenue Growth Amidst Valuation Conce - GuruFocus
Craig-Hallum Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Announces Target Price $370 - Moomoo
RBC Capital Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $345 - Moomoo
Oppenheimer Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $326 - Moomoo
Ligand Pharmaceuticals (LGND) Releases Q2 2026 Earnings: Revenue Declines but EPS Jumps - Quiver Quantitative
LGND Maintained by RBC Capital -- Price Target Raised to $345 - GuruFocus
Ligand Pharmaceuticals 2Q 2026: Revenue $63.69M, EPS $2.22— 10-Q Summary - TradingView
Ligand Pharmaceuticals (NASDAQ: LGND) lifts Q2 net income to 48,508 - Stock Titan
Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says - MarketBeat
Ligand Pharmaceuticals, Inc. : H.c. Wainwrigh - moomoo.com
RBC Adjusts PT on Ligand Pharmaceuticals to $345 From $340, Maintains Outperform Rating - marketscreener.com
TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari - Stocktwits
LIGAND PHARMACEUTICALS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $358 FROM $289 - Bitget
Ligand Pharmaceuticals Inc (LGND) (Q2 2026) Earnings Call Highli - GuruFocus
Ligand Pharmaceuticals (NASDAQ:LGND) Given New $358.00 Price Target at HC Wainwright - MarketBeat
Earnings call transcript: Ligand beats Q2 2026 estimates as shares rise - Investing.com Canada
Ligand Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary - Yahoo Finance
LGND Maintained by HC Wainwright & Co. -- Price Target Raised to $358 - GuruFocus
Ligand Pharmaceuticals Q2 Earnings Call Highlights - TradingView
Enterprise value to EBIT forward of Ligand Pharmaceuticals Incorporated – OTC:LGNXZ - TradingView
Ligand Pharmaceuticals Incorporated Stock 12‑Month Price Target Raised to $343.3, Implies 13% Upside - TradingView
Ligand Pharmaceuticals Incorporated 2026 Q2ResultsEarnings Call Presentation (NASDAQ:LGND) 2026-08-06 - Seeking Alpha
Ligand Pharmaceuticals (NASDAQ:LGND) Issues FY 2026 Earnings Guidance - MarketBeat
Is Ligand Pharmaceuticals (LGND) Trading at 69.1% Overvaluation - GuruFocus
Ligand Pharmaceuticals Incorporated reports results for the quarter ended June 30Earnings Summary - TradingView
Ligand Pharmaceuticals Q2 Adjusted Earnings, Revenue Rise; 2026 Adjusted EPS Outlook Lifted, Revenue Outlook Reaffirmed - Moomoo
Q2 2026 Ligand Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
(LGND) Ligand Pharmaceuticals Expects 2026 Adjusted EPS Range $9.00 to $9.50, vs. FactSet Est of $9.21 - marketscreener.com
Ligand Pharmaceuticals Q2 revenue rises on royalty growth - TradingView
Ligand: Q2 Earnings Snapshot - Yahoo Finance
Ligand reports Q2 2026: Revenue $63.7M, Royalties $48.0M, GAAP EPS $2.22, Adjusted EPS $2.37 - TradingView
Ligand Reports Second Quarter 2026 Financial Results - marketscreener.com
BRIEF-Ligand Pharmaceuticals Q2 EPS USD 2.22 - TradingView
Press Release: Ligand Reports Second Quarter 2026 Financial Results - Moomoo
Segall Bryant & Hamill LLC Takes $1.34 Million Position in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Adds More Than 120 Royalty Assets in XOMA Acquisition - Stock Titan
Moody National Bank Trust Division Acquires Shares of 12,147 Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Pharmaceuticals Incorporated $LGND Shares Sold by Arrowstreet Capital Limited Partnership - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Insider Andrew Reardon Sells 5,000 Shares - MarketBeat
Public Employees Retirement System of Ohio Sells 5,600 Shares of Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):